Single Cell Discoveries
PrivateLast Round
Early Funding
Jun 1, 2022
Total Funding Raised
$212,000
Company Overview
Single Cell Discoveries operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was an Early Funding round in June 2022.
Single Cell Discoveries is a biotechnology company that provides single-cell sequencing services to biopharmaceutical companies, health systems, and academic research centers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Single Cell Discoveries Comparables
Compare Single Cell Discoveries with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SingulOmics Corporation | 88% | |
| Xpress Genomics | 87% | |
| Sirona Dx | 86% |
For institutional investors. Book with your work email.
Single Cell Discoveries Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Single Cell Discoveries Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mibiton Foundation | Debt |
| Oncode Institute | Seed |
| Care Equity | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 14, 2025
Grew 21% QoQ, from 29 to 35 employees.
- Jun 1, 2022
Care Equity led the early funding round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- acquiresSep 15, 2026
On Sep 14th '26, Single Cell Discoveries BV acquires TATAA Biocenter AB, combining expertise in discovery transcriptomics, molecular analysis, assay development, and regulatory-ready bioanalysis to create an end-to-end precision biology CRO.
- hiresAug 18, 2026
On Aug 18th '26, Single Cell Discoveries BV appoints Dr. Virginia Savova to its Scientific Advisory Board to strengthen the connection between advanced transcriptomics technologies and pharmaceutical and biotechnology research.
For institutional investors. Book with your work email.
Single Cell Discoveries Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Single Cell Discoveries's valuation, stock price, and market status.
Is Single Cell Discoveries a public or private company?
Single Cell Discoveries is a private company.
What is the current stock price of Single Cell Discoveries?
Single Cell Discoveries is a private company, so its shares have no public market price. Caplight tracks Single Cell Discoveries's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Single Cell Discoveries worth (valuation)?
Valuation information for Single Cell Discoveries is not publicly available.
Can I buy Single Cell Discoveries stock?
Single Cell Discoveries shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Single Cell Discoveries's last funding round?
Single Cell Discoveries's most recent funding round was Early Funding on June 1, 2022.
Who are the main investors in Single Cell Discoveries?
Key investors in Single Cell Discoveries include Oncode Institute, Care Equity.
Will Single Cell Discoveries IPO soon?
No public IPO plans have been announced for Single Cell Discoveries.
How can I track Single Cell Discoveries secondary market activity?
Caplight tracks bids, offers, and trades in Single Cell Discoveries's shares on secondary markets.